ImmunityBio Secures $40 Million Equity Financing to Support Ongoing Business Operations


Clinical-stage immunotherapy company, ImmunityBio, has successfully executed a financing deal to bolster its working capital and continue supporting its business operations. The company entered into a securities purchase agreement for a registered direct offering with multiple institutional investors, with the issuance of common stock and warrants. The offering is expected to result in gross proceeds of approximately $40 million at closing, subject to customary closing conditions. Additionally, if fully exercised, the warrants could potentially lead to additional gross proceeds of up to $48 million. As part of the current financing, ImmunityBio also agreed to amend the terms of existing warrants issued in February 2023 to match the newly issued warrants.

Exclusive placement agent, Jefferies LLC, is overseeing the registered direct offering.

The securities offered by ImmunityBio fall under its shelf registration statement on Form S-3 (Registration No. 333-269608). A final prospectus supplement containing additional information related to the offering will be filed with the SEC and made available on their website at Interested parties can obtain electronic copies of the prospectus supplement for free by contacting Jefferies, LLC.

It is essential for potential investors to carefully review the prospectus supplement, accompanying prospectus, and other incorporated documents in their entirety before participating in this offering.

Notably, this press release is not intended to serve as an offer to sell or solicit an offer to buy securities. Any sale of these securities will comply with the securities laws of relevant states or jurisdictions, following registration or qualification.

Related Stories